$ONT

GRAHAM PETER purchased $77K of ONT

GRAHAM PETER purchased 4,860 shares of Onterris, Inc. (ONT) at $15.94 on 2026-06-03.

Original reporting
SEC EDGAR · GRAHAM PETER
Published Jun 5, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ONT
Bullish
medium confidence
Mentioned
$ONT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONTBullishLow
01

Why it matters

The most immediate tradable element is sentiment/positioning around ONT following the disclosed purchase; absent other catalysts, impact is likely limited.

02

Market read

A director’s open-market buy provides a modest bullish datapoint for ONT but lacks a fundamental trigger.

03

What to watch

No 10b5-1 plan and the purchase size is relatively small versus typical institutional flows, limiting signal strength.

Relevance 7/10Novelty 6/10Timing: Filed June 5; purchase executed June 3

Background

The filing is an SEC Form 4 reporting an insider’s open-market purchase; it does not include new operational or financial results.

Company-level read

Ticker impact

$ONTBullishMedium confidence
Context

Onterris director Graham Peter bought 4,860 shares in an open-market transaction worth about $77.5K, signaling insider accumulation.

Expected impact

Likely small/short-lived positive drift; not expected to drive a major repricing without corroborating fundamentals.

Evidence & confidence

This is a Form 4 insider purchase with a specific datapoint (size, price, date) but no accompanying company event (earnings, guidance, trial, deal).

Market effects

No sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (diversification, liquidity needs, or non-informational timing) and may not reflect near-term fundamentals.

Key entities

  • Onterris, Inc.

    Company whose director insider purchase is disclosed on SEC Form 4.

  • GRAHAM PETER

    Director who purchased 4,860 shares at $15.94 on 2026-06-03.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ONTHigh

Onterris (ONT) Slashes Guidance, Launches Board Review

Onterris Inc. (NYSE:ONT) reported Q2 revenue of $186.7M, down from $234.5M YoY, and cut 2026 guidance. EBITDA margin improved to 17.1%. The company initiated a strategic review and adopted a poison pill. Net income fell to $1.4M, and operating cash flow turned negative. Hedge fund ownership declined, while short interest rose to 10.22%.

$ONTHighAI 8/10

Why is Oxford Nanopore Technologies stock sliding today?

Oxford Nanopore Technologies' shares fell 6.5% to 162.08p after Novo Holdings sold 49 million shares at a 12.3% discount. This follows mixed reactions to the company's H1 2026 results, showing revenue growth but geographic weaknesses. The UK's FTSE 100 also declined due to Middle East tensions and rising bond yields, impacting growth stocks like Oxford Nanopore.

$MRKHighAI 9/10

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

$ONTHighAI 8/10

Why is Oxford Nanopore Technologies stock rallying today?

Oxford Nanopore Technologies' stock rose 6.6% after its interim results showed improved profitability, with gross margin expanding to 62.2% and adjusted EBITDA losses halving. The company also announced a new licensing deal expected to generate $20 million in fees. Berenberg maintained a Buy rating but lowered its price target to £2.00. The stock is still below its 52-week high of 215.6p.